close
Trend Chart on Innovative Biotherapies 26th April
News

Trend Chart on Innovative Biotherapies 26th April

FEATURE STORY

● A safe and potent anti-CD19 CAR T cell therapy

GENE THERAPY

●Chimeric antigen receptor T cell persistence and memory cell formation

DISRUPTIVE TECHNOLOGIES 

●Hemophilia A : Restoration of FVIII expression by targeted gene insertion in the FVIII

CLINICAL TRIALS-DATA 

● Avexis data reinforce effectiveness of Zolgnesma® in treating SMA type 1

● Lentiviral gene therapy in infants with SCID-X1

INDUSTRIAL LANDSCAPE & AGREEMENTS

● Novasep and Theravectys enter into a new license agreement for GMP manufacturing of lentiviral vectors

● Eli Lilly invests in Avidity Biosciences as part of new collaboration

● Gracell Bio announces fast, cost-effective CAR-T manufacturing technology

● Kite announces plans for new facility to expand cell therapy production capabilities

MISCELLANEOUS

● Medicare proposes raising CAR-T pay, but reimbursement solution years away

 

Click here to read these articles: Trend Chart on Innovative Biotherapies 26th April


COMMENTS ARE OFF THIS POST